Hematology, Transfusion and Cell Therapy最新文献

{"title":"Donor DNA: Embedding self-regulation into blood donation culture","authors":"Dr RishiRaj Sinha","doi":"10.1016/j.htct.2025.106241","DOIUrl":"10.1016/j.htct.2025.106241","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 2","pages":"Article 106241"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145954752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on clinical characteristics and outcomes of non-tuberculous mycobacterial pulmonary infections after hematopoietic stem cell transplantation: A retrospective cohort study","authors":"Marhaba Khan, Tahir Abdul Qadir","doi":"10.1016/j.htct.2025.106090","DOIUrl":"10.1016/j.htct.2025.106090","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 2","pages":"Article 106090"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145924511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early detection of cardiotoxicity in pediatric and adolescent patients with cancer treated with anthracyclines in Northeastern Brazil","authors":"Jéssica Laureano Martins ,&nbsp;Fabiana Gomes Aragão Magalhães Feitosa ,&nbsp;Maria Verônica Câmara dos Santos ,&nbsp;Thaysa Maria Gama Albuquerque Leão de Menezes ,&nbsp;Andrea Dantas Sena ,&nbsp;Edinalva Pereira Leite Rodrigues ,&nbsp;Marcela Beatriz Alves Lopes ,&nbsp;Júlia Laís dos Santos ,&nbsp;Maria do Carmo Menezes Bezerra Duarte","doi":"10.1016/j.htct.2026.106255","DOIUrl":"10.1016/j.htct.2026.106255","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the early detection of cardiotoxicity using echocardiography in children and adolescents with cancer treated with anthracyclines.</div></div><div><h3>Methods</h3><div>This cross-sectional study was conducted in a tertiary pediatric oncology center in Northeastern Brazil between January 2018 and December 2022. Eligible participants were under 19-year-old patients with cancer treated with anthracyclines presenting left ventricular ejection fraction ≥55% (assessed using the biplane Simpson’s method) and abnormal left ventricular global longitudinal strain.</div></div><div><h3>Results</h3><div>A total of 45 patients meeting the inclusion criteria were included. Among them, 19 patients (42.2%) showed reduced ejection fraction or left ventricular global longitudinal strain (or both) compared with baseline values, and 57.9% were asymptomatic. The most prevalent cancer was leukemia (55.5%), followed by lymphoma (20.0%). A total of 75.6% of participants were undergoing cancer treatment at the time of diagnosis of cardiotoxicity. An isolated left ventricular ejection fraction reduction occurred in 26.3% of patients, isolated left ventricular global longitudinal strain reduction in 47.4% of patients, and both alterations were experienced by 26.3% of patients.</div></div><div><h3>Conclusions</h3><div><strong>A</strong>nthracycline-induced cardiotoxicity is a relevant adverse effect in cancer treatment, especially in patients with leukemia and lymphoma. Echocardiography, especially the assessment of left ventricular global longitudinal strain, plays a critical role in the early and subclinical detection of cardiotoxicity in pediatric patients.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 2","pages":"Article 106255"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146145167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SYNTHESIS AND GALLIUM-68 RADIOLABELING OF A PEPTIDE FOR THE DETECTION OF AMYLOID FIBRILS IN ALZHEIMER’S DISEASE","authors":"Carlos Eduardo Monforte de Oliveira ,&nbsp;Fernanda Ferreira Mendonça ,&nbsp;Danielle Vieira Sobral ,&nbsp;Aline Morais de Souza ,&nbsp;Caiubi Rodrigues de Paula Santos ,&nbsp;Marycel Rosa Felisa Figols de Barboza ,&nbsp;Leonardo Lima Fuscaldi ,&nbsp;Luciana Malavolta","doi":"10.1016/j.htct.2026.106287","DOIUrl":"10.1016/j.htct.2026.106287","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction/Rationale&lt;/h3&gt;&lt;div&gt;The development of peptide-based radiopharmaceuticals for the detection of amyloid fibrils associated with Alzheimer’s disease requires the formation of stable complexes with high radiochemical yield and purity. Specific fragments of the amyloid-ß peptide, when conjugated to chelating agents such as DOTA and radiolabeled with metallic radionuclides, represent a promising strategy for the development of molecular imaging tracers for nuclear medicine applications.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;The aim of this study was to synthesize an amyloid-ß peptide fragment, conjugate it to the DOTA chelator, and assess the radiochemical yield, purification efficiency, radiochemical purity, and stability of gallium-68 labeling.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and Methods&lt;/h3&gt;&lt;div&gt;The amyloid-ß peptide central fragment Aß16-20 (KLVFF) was synthesized and conjugated to the DOTA chelator via solid-phase peptide synthesis. The DOTA-KLVFF conjugate was cleaved and analyzed by high-performance liquid chromatography (HPLC) to assess its chromatographic profile prior to radiolabeling. Radiolabeling was performed manually with [68Ga]GaCl3 eluted from a 68Ge–68Ga generator with 6 mL of 0.1 M HCl (∼12.21 mCi/mL) and purified in a cationic filter. Approximately 500 µL of eluate was added to 40 µL of peptide (830 µg/mL), solubilized in 1 mL of 0.2 M sodium acetate buffer (pH 4.0), followed by heating at 95°C for 15 minutes. The radiolabeled peptide was purified using a Sep-Pak C18 cartridge with 50% ethanol. The chromatographic behavior and radiochemical purity of [Ga]Ga-DOTA-KLVFF were evaluated by instant thin-layer chromatography (iTLC), before and after purification, respectively using ammonium acetate/methanol (AcONH4:MeOH, 1:1) as mobile phase. Radiochemical stability was qualitatively assessed by iTLC at 0, 30 min, 1h, and 1.5h.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;The DOTA-KLVFF peptide was successfully synthesized with a yield of 80%. After purification, preliminary radiolabeling with 68Ga achieved a radiochemical yield of approximately 89%. The purified product, [68Ga]Ga-DOTA-KLVFF, exhibited a radiochemical purity of 99%. iTLC analysis showed a retention factor (Rf) of 0.9–1.0 for the radiolabeled peptide, while free [68Ga]GaCl3 presented an Rf of 0.0–0.1, indicating effective separation between the desired product and radiochemical impurities. A preliminary stability study demonstrated maintenance of radiochemical purity over time, with values of 94.3 ± 2.6% at time zero, 91.0 ± 0.6% after 30 min, 87.4 ± 0.4% after 1h and 94.4 ± 3.6% after 1.5h. These results indicate efficient complex formation and satisfactory short-term stability of [Ga]Ga-DOTA conjugate under the evaluated conditions.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;The central amyloid-ß peptide fragment Aß16–20 (KLVFF) conjugated to DOTA exhibited efficient gallium-68 radiolabeling, high radiochemical yield, effective purification, and excellent radi","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 ","pages":"Article 106287"},"PeriodicalIF":1.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147451937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RIGHT PYELOCALICEAL DUPLICATION WITH FUNCTIONAL EXCLUSION OF THE LOWER MOIETY AND SIGNS OF REFLUX: APPLICATION OF 99MTC-DTPA RENAL SCINTIGRAPHY IN COMPLEX FUNCTIONAL ASSESSMENT","authors":"Mariana Maitto,&nbsp;Barbara Rayne Santos de Alencar,&nbsp;Barbara Juarez Amorim,&nbsp;Allan Oliveira Santos,&nbsp;Celso Dario Ramos,&nbsp;Tomás Agnello,&nbsp;Elba C. S. Camargo Etchebehere,&nbsp;Mariana da Cunha Lopes de Lima","doi":"10.1016/j.htct.2026.106339","DOIUrl":"10.1016/j.htct.2026.106339","url":null,"abstract":"<div><div><em>Introduction</em>: Congenital anomalies of the urinary tract account for 30–50% of chronic kidney disease causes in the pediatric population. Pyelocaliceal duplication is one of the most frequent malformations and may present with ureteral ectopia, obstruction, or vesicoureteral reflux (VUR), directly affecting renal function. Dynamic renal scintigraphy with 99mTc-DTPA plays a key role in evaluating glomerular function and diuretic response, particularly in complex cases such as the one reported here, in which vesicoureteral reflux on the right side was demonstrated during the excretory phase. <em>Materials and methods</em>: A 16-year-old patient with right pyelocaliceal duplication, a history of grade IV right-sided VUR, multiple urologic surgeries, recurrent urinary tract infections, and stage 3A chronic kidney disease. 99mTc-DMSA scintigraphy revealed functional asymmetry (right kidney 21%, with lower moiety exclusion) and bilateral cortical scars. Dynamic renal scintigraphy with 99mTc-DTPA showed reduced arterial flow and function in the upper moiety and absence of function in the lower moiety. Partial tracer retention was observed up to the 25th minute in both kidneys, with good response to furosemide. During the late dynamic phase, vesicoureteral reflux of the tracer to the right lower moiety became evident, accentuated after diuretic administration. <em>Discussion</em>: Diuretic-enhanced dynamic renal scintigraphy with 99mTc-DTPA is considered the gold standard for evaluating upper urinary tract obstruction. As the tracer is purely glomerularly filtered, it allows functional and excretory drainage assessment. Studies show that about 10% of patients with complete renal duplication progress to functional loss in one moiety, and early detection of such exclusion can prevent unnecessary interventions. 99mTc-DTPA scintigraphy also enables indirect identification of vesicoureteral reflux even without cystography, as in this case, where reflux of the tracer into the functionally excluded moiety supported the diagnosis and guided therapeutic decisions. <em>Conclusion</em>: This case demonstrates the importance of dynamic renal scintigraphy with 99mTc-DTPA in assessing renal function in complex urologic malformations. The identification of functional exclusion of the lower moiety and vesicoureteral reflux was fundamental in multidisciplinary management and treatment planning.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 ","pages":"Article 106339"},"PeriodicalIF":1.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147452038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"THERANOSTICS OF DIFFERENTIATED THYROID CANCER WITH IODINE-131: DIAGNOSTIC INTEGRATIONS, THERAPEUTIC RESPONSE, AND CHALLENGES OF TRANSLATIONAL RESEARCH","authors":"Victória Perez Huada,&nbsp;Carlos Takahiro Chone","doi":"10.1016/j.htct.2026.106348","DOIUrl":"10.1016/j.htct.2026.106348","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction/Rationale&lt;/h3&gt;&lt;div&gt;Differentiated Thyroid Cancer (DTC) is a well-established model of the theranostic concept, combining functional diagnosis and targeted therapy through the use of Iodine-131. Population-based studies indicate that thyroid cancer incidence has steadily increased and is projected to rise until 2040 (GLOBOCAN), showing its clinical relevance. Despite high survival rates, DTC biological heterogeneity has revealed important limitations in the uniform application of radioiodine therapy, predominantly affecting tumors with partial dedifferentiation, aggressive behavior, or refractoriness to the use of Iodine-131. Advances in hybrid imaging, molecular biology, and risk stratification emphasize the need for translational approaches integrating clinical, functional, and molecular data to improve diagnostic accuracy and therapeutic precision.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;This study aims to critically analyze the contemporary literature on the use of Iodine-131 in the theranostic approach to DTC, focusing on diagnostic advances, predictors of therapeutic response, mechanisms of radioiodine resistance, and translational research challenges.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and Methods&lt;/h3&gt;&lt;div&gt;A systematic search was conducted in PubMed, MEDLINE, and SciELO databases using the keywords: “Theranostics”; “Thyroid Neoplasms”; “Radioactive Iodine”; “Combined Modality Therapy”; “Differentiated Carcinoma”. A total of 25 articles written in English, Portuguese, and Spanish published between 2015 and 2024 were included. Results: The present study shows that integrating hybrid imaging techniques with molecular and clinical parameters enhances diagnostic accuracy, disease extent evaluation, and risk stratification. Findings demonstrate that genetic alterations, NIS expression, and tumor phenotypic characteristics directly influence Iodine-131 uptake. Personalized strategies, including patient selection, tumor redifferentiation and dose modulation, show promise, though methodological and translational limitations persist.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Iodine-131 theranostics remains central in DTC management, representing an oncology paradigm. Tumor NIS expression levels are strongly associated with Iodine-131 absorption, suggesting its potential as a biomarker for patient selection. Additionally, pharmacological redifferentiation strategies, such as MAPK pathway inhibition, have shown promise in restoring radioiodine sensitivity in refractory tumors, highlighting actionable translational approaches. In this regard, the integration of hybrid imaging with molecular profiling was shown to improve staging accuracy, disease extent evaluation, and risk stratification, enabling more precise therapies. Nevertheless, the present abstract emphasizes the maintenance of significant barriers to clinical implementation such as methodological heterogeneity, small sample sizes, and lack of standardized protocols. Therefore, st","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 ","pages":"Article 106348"},"PeriodicalIF":1.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147452039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DEVELOPMENT OF A NEW TRIVALENT CHELATING AGENT AND STUDY OF ITS COMPLEXATION TO FORM A COMPLEX WITH OXORRHENIUM(V)","authors":"Julia Pontes Gomes,&nbsp;Victor Marcelo Deflon","doi":"10.1016/j.htct.2026.106289","DOIUrl":"10.1016/j.htct.2026.106289","url":null,"abstract":"<div><div>This project consists of the synthesis and characterization of a trivalent and polydentate ligand (H3L), developed to form an oxorenium(V) complex. This complex functions as a non-radioactive model for oxotechnetium(V) analogs, given its importance in nuclear medicine, especially in the diagnosis and treatment of cancer. The ligand was designed to occupy all coordination positions around the rhenium metal center, forming a hexacoordinated complex. Aldehyde functions located in the ligand enable bioconjugation reactions, ensuring specificity. The synthesis of the H3L ligand involved a reductive amination reaction followed by alkylation under an inert atmosphere, obtaining H3L as a solid after solvent removal under vacuum. The polydentate ligand was characterized by spectroscopic methods, FT-IR and ¹H and ¹³C NMR, and is being studied regarding a coordination reaction for the formation of an oxorrhenium(V) complex by reaction from [ReOCl3(PPh3)2]. The H3L ligand was successfully obtained and structurally characterized. After completing the characterization of the formed oxorrhene complex, further studies include labeling with technetium-99m and bioconjugation with tumor-specific biomolecules, aiming at clinical applications in oncological nuclear medicine.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 ","pages":"Article 106289"},"PeriodicalIF":1.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147452045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PRELIMINARY MIRNA PROFILING IN ERP29-SILENCED TONGUE SQUAMOUS CELL CARCINOMA HIGHLIGHTS CANCER-RELATED PATHWAYS","authors":"Bianca Piovesan Melchiori Peruzza,&nbsp;Carmen Silvia Passos Lima,&nbsp;Juliana Carron,&nbsp;Gustavo Jacob Lourenço","doi":"10.1016/j.htct.2026.106280","DOIUrl":"10.1016/j.htct.2026.106280","url":null,"abstract":"<div><h3>Introduction</h3><div>Head and neck squamous cell carcinoma represent a major global health burden, with tongue tumors being the most common subtype. Endoplasmic reticulum (ER) protein 29 (ERp29) is a chaperone protein, encoded by the ERP29 gene on chromosome 12. It is an ER-resident and its main function is the protein folding and trafficking. Although Erp29 has been implicated in tumor biology, its functional role in tongue squamous cell carcinoma (TSCC) remains poorly understood.</div></div><div><h3>Objective</h3><div>To identify microRNA (miRNA) alterations and associated signaling pathways induced by ERP29 silencing in TSCC cells.</div></div><div><h3>Materials and methods</h3><div>SCC-4 TSCC cells (ATCC, CRL-1624) were edited using CRISPR/Cas9 to generate ERP29 knockout clones. miRNA expression was profiled using nCounter® miRNA Expression Assay Kit (NanoString®), normalized to counts-per-million, and analyzed for differential expression versus parental SCC-4 cells. Validated miRNA targets were retrieved from the multiMiR database and subjected to KEGG and Reactome enrichment analyses. All analyses were performed in the R statistical environment.</div></div><div><h3>Results</h3><div>ERP29 silencing was associated with down-regulation of several miRNAs, including hsa-miR-27b-3p, hsa-miR-30a-5p, hsa-miR-19b-3p, hsa-miR-320e, hsa-miR-378i, and hsa-miR-126-3p, has-miR-1306-5p, has-miR-616-3p (absolute log2 fold-change &gt;8). KEGG analysis revealed strong enrichment of proteoglycans in cancer (hsa05205) and PI3K/AKT signaling (hsa04151), encompassing canonical TSCC drivers such as TP53 (Entrez 7157), PIK3CA (5290), EGFR (1956), HRAS (3265), AKT1 (207), PTEN (5728), and MAPK1/3 (5594/5595). Reactome enrichment highlighted pathways such as signaling by ALK in cancer (HSA-9700206), NOTCH1 signaling (HSA-2644603), and AKT1 E17K activation (HSA-5674400), all related to growth-factor signaling, extracellular matrix remodeling, and immune crosstalk.</div></div><div><h3>Conclusion</h3><div>These preliminary data from a single TSCC cell line suggest that Erp29 loss could reshape the miRNA landscape and enriches gene networks linked to PI3K/AKT, NOTCH, and proteoglycan-mediated cancer progression. The results are preliminary and require validation in additional cell lines and clinical samples to confirm the role of Erp29 in tumor-host interactions.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 ","pages":"Article 106280"},"PeriodicalIF":1.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147452050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GOLD(I) COMPLEX AUDMAP PROMOTES APOPTOTIC RESPONSES AND INHIBITS PROLIFERATION AND MIGRATION IN SK-MEL-28 HUMAN MELANOMA CELLS","authors":"Isabela Carvalho Diniz,&nbsp;Fernanda Van Petten Vasconcelos Azevedo,&nbsp;Ericka Francislaine Dias Costa,&nbsp;Jennyfer Castro da Silva,&nbsp;Camilla Abbehausen,&nbsp;Carmen Silvia Passos Lima","doi":"10.1016/j.htct.2026.106288","DOIUrl":"10.1016/j.htct.2026.106288","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Metal-based chemotherapeutic agents, particularly platinum compounds, are widely used in cancer treatment; however, they are limited by systemic toxicity and drug resistance, highlighting the need for novel metallodrugs. Gold-based complexes have emerged as promising candidates due to their distinct mechanisms of action and notable antitumoral activity. Melanoma remains a highly aggressive malignancy with limited therapeutic options in advanced stages. Although several gold-based compounds have shown preclinical antitumoral potential, their effects in melanoma models remain insufficiently explored.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;To evaluate the in vitro antitumoral properties of the gold(I) complex (PPh3)Au(DMAP) (AuDMAP) in human melanoma cells.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methodology&lt;/h3&gt;&lt;div&gt;AuDMAP was evaluated in SK-MEL-28 melanoma cells, with non-tumoral HaCaT keratinocytes used as a comparative model. Cell viability and proliferation were assessed using MTT and SRB colorimetric assays. Cell migration was evaluated through the wound healing assay. Intracellular reactive oxygen species (ROS) levels were measured using the DCFH-DA assay and expressed as mean fluorescence intensity (MFI). Cell cycle distribution and cell death were evaluated by flow cytometry using 7-AAD and Annexin V-FITC/7-AAD staining, respectively. Transcriptional analysis was performed by quantitative PCR (qPCR).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;AuDMAP markedly reduced melanoma cell viability and proliferation in the low-nanomolar range, with an IC50 of ∼35.1 nM at 24h and 48h, showing greater inhibitory activity than cisplatin at concentrations = 34.4 µM (p = 0.001). In non-tumoral HaCaT keratinocytes, IC50 was ∼46,1 nM, indicating limited in vitro selectivity under the tested conditions. Based on these data, the 34.4 nM dose was selected for subsequent assays. At this concentration, AuDMAP significantly impaired melanoma cell migration, reducing wound closure percentage when compared to control, at both 24h (4.7% vs. 40.5%; p = 0.05) and 48h (1.6% vs. 74.6%; p = 0.05). In contrast, keratinocytes exhibited higher migratory activity, with increased wound closure at 24h (76.1% vs. 48.9%; p = 0.05) and 48h (85.8% vs. 48.9%; p = 0.05). Treatment with AuDMAP increased ROS levels in melanoma cells, expressed by a higher MFI at 24h (1154 vs. 637; p = 0.05) and 48h (1334 vs. 640; p = 0.05). In HaCaT keratinocytes, MFI was higher than control at 24h (1090 vs. 341; p = 0.05), but did not differ significantly at 48h (916 vs. 490; p &gt; 0.05). No significant differences were found in melanoma cell cycle distribution. Conversely, analysis of cell death pathways revealed a predominance of early apoptotic markers in melanoma cells following AuDMAP treatment, at 24h (49.8% vs. 0.0%; p = 0.0001) and 48h (85.3% vs. 0.1%; p = 0.0001). In keratinocytes, no significant differences were observed at 24h (27.0% vs. 1.1%; p = 0.0001), whereas a significant in","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 ","pages":"Article 106288"},"PeriodicalIF":1.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147452110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FDG PET/CT AND PSMA PET/CT IN EPITHELIOID SARCOMA STAGING: A CASE REPORT","authors":"Ellen Nogueira Lima,&nbsp;Natália Tobar Toledo Prudente da Silva,&nbsp;Mayara Silva,&nbsp;Allan de Oliveira Santos,&nbsp;José Barreto Campello Carvalheira,&nbsp;Maurício Etchebehere,&nbsp;Elba C.S.C. Etchebehere","doi":"10.1016/j.htct.2026.106327","DOIUrl":"10.1016/j.htct.2026.106327","url":null,"abstract":"<div><h3>Introduction</h3><div>Epithelioid sarcoma (ES) is a rare malignant soft-tissue neoplasm characterized by indolent growth, most commonly arising in the distal extremities, with a predilection for the hands and feet. ES poses a clinical diagnostic challenge, as its presentation may mimic benign conditions, particularly inflammatory or granulomatous lesions. ¹8F-FDG PET/CT is used for primary staging of soft tissue sarcomas, including ES. Although no studies have focused on PSMA and ES to date, the Prostate Specific Membrane Antigen (PSMA) may be an alternative for diagnosing and potentially treating these patients due to its Theranostic capabilities. We present a case of epithelioid sarcoma and evaluate the diagnostic performance of ¹8F-PSMA PET/CT compared to ¹8F-FDG PET/CT. Ethical Approval (CAAE: 30476720.9.0000.5404).</div></div><div><h3>Case presentation</h3><div>A 34-year-old man presented with a lesion on the plantar region of the right foot with progressive growth over 9 months and weight loss. MRI showed a well-defined, lobulated, heterogeneous mass measuring 90 × 71 × 64 mm, with a focus of cystic degeneration, located on the plantar and medial surfaces of the midfoot. Histopathology was consistent with ES. A staging 18F-FDG PET/CT showed marked hypermetabolism in the ES as well as in locoregional lymph node metastases in the right popliteal fossa and peri-bronchial lymph nodes, in lung nodules, and in the distal portion of the tibia. After 24 hours, an 18F-PSMA PET/CT scan was performed. The comparison of 18F-PSMA PET/CT and 18F-FDG PET/CT showed higher PSMA uptake in the ES (SUVPSMA = 24; SUVFDG = 14); similar uptake in popliteal fossae lymph node metastases (SUVPSMA = 9; SUVFDG = 11) and peri-bronchial lymph nodes (SUVPSMA = 7; SUVFDG = 9); lower uptake in lung nodes (SUVPSMA = 3; SUVFDG = 10) and tibia (SUVPSMA = 5; SUVFDG = 15).</div></div><div><h3>Conclusion</h3><div>This report highlights the potential role of PSMA PET/CT in staging of patients with ES, demonstrating lesion detection comparable to that of FDG PET/CT while also offering a Theranostics perspective.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 ","pages":"Article 106327"},"PeriodicalIF":1.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147452163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}